Transform Wealth LLC Buys 6,014 Shares of Novo Nordisk A/S (NYSE:NVO)

Transform Wealth LLC grew its stake in shares of Novo Nordisk A/S (NYSE:NVO) by 6.7% during the fourth quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor owned 95,317 shares of the company’s stock after purchasing an additional 6,014 shares during the period. Transform Wealth LLC’s holdings in Novo Nordisk A/S were worth $8,199,000 as of its most recent SEC filing.

Other institutional investors also recently bought and sold shares of the company. Natixis Advisors LLC lifted its position in Novo Nordisk A/S by 2.7% during the third quarter. Natixis Advisors LLC now owns 3,074,876 shares of the company’s stock valued at $366,125,000 after buying an additional 80,070 shares during the period. Norman Fields Gottscho Capital Management LLC boosted its stake in Novo Nordisk A/S by 45.3% during the fourth quarter. Norman Fields Gottscho Capital Management LLC now owns 63,732 shares of the company’s stock worth $5,482,000 after acquiring an additional 19,870 shares in the last quarter. Talbot Financial LLC purchased a new stake in Novo Nordisk A/S in the fourth quarter worth about $4,066,000. Versant Capital Management Inc bought a new position in shares of Novo Nordisk A/S during the fourth quarter valued at approximately $86,000. Finally, Zions Bancorporation N.A. lifted its holdings in shares of Novo Nordisk A/S by 57.0% during the third quarter. Zions Bancorporation N.A. now owns 18,535 shares of the company’s stock valued at $2,207,000 after purchasing an additional 6,726 shares during the last quarter. 11.54% of the stock is owned by institutional investors.

Novo Nordisk A/S Stock Down 5.2 %

Shares of Novo Nordisk A/S stock opened at $78.74 on Tuesday. The company has a quick ratio of 0.75, a current ratio of 0.94 and a debt-to-equity ratio of 0.43. Novo Nordisk A/S has a twelve month low of $78.17 and a twelve month high of $148.15. The company has a market cap of $353.33 billion, a price-to-earnings ratio of 25.48, a price-to-earnings-growth ratio of 0.84 and a beta of 0.45. The company’s 50 day moving average is $97.15 and its 200 day moving average is $116.47.

Wall Street Analyst Weigh In

NVO has been the subject of a number of analyst reports. BNP Paribas raised Novo Nordisk A/S to a “strong-buy” rating in a research report on Monday, December 2nd. Sanford C. Bernstein raised Novo Nordisk A/S from an “underperform” rating to a “market perform” rating in a research report on Monday, January 6th. BMO Capital Markets dropped their price target on shares of Novo Nordisk A/S from $156.00 to $105.00 and set an “outperform” rating on the stock in a research note on Monday, December 23rd. StockNews.com cut shares of Novo Nordisk A/S from a “strong-buy” rating to a “buy” rating in a report on Sunday, December 29th. Finally, UBS Group upgraded shares of Novo Nordisk A/S from a “sell” rating to a “buy” rating in a research note on Wednesday, January 8th. One equities research analyst has rated the stock with a hold rating, seven have issued a buy rating and one has given a strong buy rating to the stock. According to data from MarketBeat.com, the stock has an average rating of “Buy” and a consensus price target of $140.20.

About Novo Nordisk A/S

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.